Galectin-3 in urine of cancer patients: stage and tissue specificity
- First Online:
- Cite this article as:
- Balasubramanian, K., Vasudevamurthy, R., Venkateshaiah, S.U. et al. J Cancer Res Clin Oncol (2009) 135: 355. doi:10.1007/s00432-008-0481-4
- 182 Downloads
Galectin-3 has been implicated in advanced stage of cancer disease. In the current study we examined the possibility of urinary galectin-3 levels to stage cancer disease and to follow up therapy.
Urine was collected from all types of cancer patients at different stages including patients undergoing radio/chemotherapy. Galectin-3 level was determined by anti-galectin-3 based ELISA and agglutination assays. Immunoblotting and purification on lactosyl affinity column further confirmed the presence of galectin-3.
Cancer samples exhibited stage dependent expression of galectin-3 approx. ranging from 1.0 to 3.3, 4.4 to 5.4, 5.4 to 24.7, 13.1 to 31.9, 13.9 to 32.9 ng/mg C (creatinine) for stage I–V, respectively, at P ~ <0.05 level. Galectin-3 levels were decreased by approx. threefolds after 5th day of therapy.
Sample collection being simple and non-invasive, urinary galectin-3 may be used as a potential diagnostic tool for monitoring or follow up of the stage of cancer disease.